Hiroshi Okamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hiroshi Okamoto has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Yusuke Taniyama
Department of Surgery Tohoku University Graduate School of Medicine Sendai Japan
14 shared publications - Chiaki Sato
Department of Surgery, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Miyagi, Japan
10 shared publications - Fumiyoshi Fujishima
Department of Pathology, Tohoku University Hospital, Sendai, Japan
9 shared publications - Takashi Kamei
Department of Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan
9 shared publications - Hironobu Sasano
Department of Pathology, Tohoku University Graduate School of Medicine, Sendai, Japan
8 shared publications Takashi Kamei
Department of Surgery, Graduate School of Medicine, Tohoku University, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan
8 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Cancer Science
3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer
Esophageal cancer is the seventh most common cancer worldwide, and early detection is crucial for improving long‐term survival. However, reliable noninvasive biomarkers for early‐stage disease remain limited. In this study, we aimed to identify novel biomarkers for early‐stage esophageal cancer through comprehensive metabolomic analyses of plasma and urine samples from patients and healthy individuals. Metabolomic profiling revealed that 3‐indoxyl sulfate (3‐IS) was consistently elevated in both plasma and urine of esophageal cancer patients. As esophageal cancer cells do not directly produce 3‐IS, its elevation may reflect cancer‐associated systemic metabolic alterations. O ‐acetylcarnitine ( O ‐AC) was identified as the most significantly increased metabolite in plasma, and in vitro analyses suggested a possible association with tumor‐related metabolic changes. Receiver operating characteristic analyses (ROC) demonstrated that the combined plasma and urinary 3‐IS model achieved an area under the curve (AUC) of 0.863 in Stage I/II disease, whereas plasma O ‐AC achieved an AUC of 0.902. Bootstrap resampling provided internal validation; however, the discovery and evaluation were performed within the same single‐center cohort. These results suggest that 3‐IS and O ‐AC are promising candidate biomarkers that distinguish patients with esophageal cancer from healthy individuals, but further validation of their disease specificity and diagnostic performance is required in independent multicenter cohorts including clinically relevant disease‐control groups.
- 9 November 2026
- Published by Wiley in Cancer Science
Open Access3‐Indoxyl Sulfate and O ‐Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer
Esophageal cancer is the seventh most common cancer worldwide, and early detection is crucial for improving long‐term survival. However, reliable noninvasive biomarkers for early‐stage disease remain limited. In this study, we aimed to identify novel biomarkers for early‐stage esophageal cancer through comprehensive metabolomic analyses of plasma and urine samples from patients and healthy individuals. Metabolomic profiling revealed that 3‐indoxyl sulfate (3‐IS) was consistently elevated in both plasma and urine of esophageal cancer patients. As esophageal cancer cells do not directly produce 3‐IS, its elevation may reflect cancer‐associated systemic metabolic alterations. O ‐acetylcarnitine ( O ‐AC) was identified as the most significantly increased metabolite in plasma, and in vitro analyses suggested a possible association with tumor‐related metabolic changes. Receiver operating characteristic analyses (ROC) demonstrated that the combined plasma and urinary 3‐IS model achieved an area under the curve (AUC) of 0.863 in Stage I/II disease, whereas plasma O ‐AC achieved an AUC of 0.902. Bootstrap resampling provided internal validation; however, the discovery and evaluation were performed within the same single‐center cohort. These results suggest that 3‐IS and O ‐AC are promising candidate biomarkers that distinguish patients with esophageal cancer from healthy individuals, but further validation of their disease specificity and diagnostic performance is required in independent multicenter cohorts including clinically relevant disease‐control groups.
- Open Access
The Evolution of Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: Past Achievements, Current Standards, and Future Perspectives
Neoadjuvant treatment has become an integral component of multidisciplinary management for resectable esophageal squamous cell carcinoma (ESCC). Over recent decades, treatment has evolved from surgery alone to postoperative chemotherapy, neoadjuvant chemotherapy, intensified systemic therapy, neoadjuvant chemoradiotherapy, and, more recently, the incorporation of immune checkpoint inhibitors into curative-intent treatment. This evolution has been driven by persistent challenges including systemic recurrence, locoregional failure, treatment-related toxicity, and heterogeneous treatment response. This review traces the evolution of neoadjuvant treatment for resectable ESCC through landmark clinical trials that have shaped current practice. We discuss the transition from postoperative to neoadjuvant chemotherapy, the development of intensified chemotherapy and neoadjuvant chemoradiotherapy, and the emergence of immunotherapy, distinguishing the established role of adjuvant nivolumab from the emerging role of neoadjuvant immunochemotherapy. We then examine the unresolved relative roles of these strategies and the challenges in treatment selection. Finally, we discuss future directions centered on accurate response assessment, circulating tumor DNA-based molecular residual disease assessment, and response-adapted treatment, with particular emphasis on organ-preserving strategies after a clinical complete response. Although active surveillance has emerged as a potential alternative to immediate surgery in carefully selected patients, accurate identification of residual disease and appropriate surveillance remain essential. Future advances may therefore shift the focus from treatment intensification alone toward response-adapted strategies that can maintain oncological safety while potentially enabling organ preservation.
Open AccessThe Evolution of Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma: Past Achievements, Current Standards, and Future Perspectives
Neoadjuvant treatment has become an integral component of multidisciplinary management for resectable esophageal squamous cell carcinoma (ESCC). Over recent decades, treatment has evolved from surgery alone to postoperative chemotherapy, neoadjuvant chemotherapy, intensified systemic therapy, neoadjuvant chemoradiotherapy, and, more recently, the incorporation of immune checkpoint inhibitors into curative-intent treatment. This evolution has been driven by persistent challenges including systemic recurrence, locoregional failure, treatment-related toxicity, and heterogeneous treatment response. This review traces the evolution of neoadjuvant treatment for resectable ESCC through landmark clinical trials that have shaped current practice. We discuss the transition from postoperative to neoadjuvant chemotherapy, the development of intensified chemotherapy and neoadjuvant chemoradiotherapy, and the emergence of immunotherapy, distinguishing the established role of adjuvant nivolumab from the emerging role of neoadjuvant immunochemotherapy. We then examine the unresolved relative roles of these strategies and the challenges in treatment selection. Finally, we discuss future directions centered on accurate response assessment, circulating tumor DNA-based molecular residual disease assessment, and response-adapted treatment, with particular emphasis on organ-preserving strategies after a clinical complete response. Although active surveillance has emerged as a potential alternative to immediate surgery in carefully selected patients, accurate identification of residual disease and appropriate surveillance remain essential. Future advances may therefore shift the focus from treatment intensification alone toward response-adapted strategies that can maintain oncological safety while potentially enabling organ preservation.
- 1 June 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 74 (9) , 917-921
Harvest of a pedicled omental flap preserving the right gastroepiploic artery for gastric conduit reconstruction in multistage surgery for aortoesophageal fistula
Aortoesophageal fistula is a rare but highly fatal condition. Thoracic endovascular aortic repair has led to improved early outcomes. However, subsequent aortic replacement, esophagectomy, and gastrointestinal reconstruction are required to achieve long-term survival. Conventional pedicled flaps using both gastroepiploic arteries can prevent gastric conduit reconstruction, requiring small or large intestinal substitutes associated with greater surgical invasiveness. We developed the pedicled omental flap technique preserving the right gastroepiploic artery, which enabled simultaneous gastric conduit preparation and omental harvest in a multistage surgery. After a specific interval following esophagectomy, the omental flap was mobilized while preserving right gastroepiploic perfusion, and a gastric conduit was created. Both were evaluated via indocyanine green imaging. The omental flap was delivered into the thoracic cavity for later graft coverage. Meanwhile, the gastric conduit was left in situ for delayed reconstruction. This method reduced invasiveness and facilitated staged treatment of aortoesophageal fistula with improved surgical flexibility.
- 1 June 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 74 (9) , 917-921
Harvest of a pedicled omental flap preserving the right gastroepiploic artery for gastric conduit reconstruction in multistage surgery for aortoesophageal fistula
Aortoesophageal fistula is a rare but highly fatal condition. Thoracic endovascular aortic repair has led to improved early outcomes. However, subsequent aortic replacement, esophagectomy, and gastrointestinal reconstruction are required to achieve long-term survival. Conventional pedicled flaps using both gastroepiploic arteries can prevent gastric conduit reconstruction, requiring small or large intestinal substitutes associated with greater surgical invasiveness. We developed the pedicled omental flap technique preserving the right gastroepiploic artery, which enabled simultaneous gastric conduit preparation and omental harvest in a multistage surgery. After a specific interval following esophagectomy, the omental flap was mobilized while preserving right gastroepiploic perfusion, and a gastric conduit was created. Both were evaluated via indocyanine green imaging. The omental flap was delivered into the thoracic cavity for later graft coverage. Meanwhile, the gastric conduit was left in situ for delayed reconstruction. This method reduced invasiveness and facilitated staged treatment of aortoesophageal fistula with improved surgical flexibility.
- Open Access
- 1 February 2026
- Published by AIP Publishing in AIP Advances
- Vol. 16 (2)
Rapid detection of Fusobacterium nucleatum in saliva using magnetic flux change
We have developed a low-cost, rapid, and highly sensitive antigen test for Fusobacterium Nucleatum that utilizes the antigen-antibody reaction between magnetic nanoparticles and biological materials (antigens), which changes the magnetic flux passing through the small pickup coil. The magnetic flux of the pickup coil decreased with increasing antigen concentration because the density of magnetic nanoparticles decreased with increasing antigen concentration. The driving coil was air-cooled to reduce thermal drift, and the size of the differential pickup coil was reduced to achieve a high signal-to-noise ratio in magnetic flux measurements. After the antigen-antibody reaction, the magnetic nanoparticles and antigens are agglutinated by magnetic force, reducing the influence of contaminants and allowing the concentration of Fusobacterium Nucleatum to be evaluated without a washing step. The method was validated using samples collected from 28 individuals. The results showed a strong correlation with qPCR analysis (correlation coefficient = 0.69, p < 0.0001), highlighting the accuracy and precision comparable to conventional qPCR systems. The proposed approach offers several advantages for bacterial detection: low cost, rapid evaluation, high sensitivity, and minimal interference from contaminants.
- 1 February 2026
- Published by AIP Publishing in AIP Advances
- Vol. 16 (2)
Open AccessRapid detection of Fusobacterium nucleatum in saliva using magnetic flux change
We have developed a low-cost, rapid, and highly sensitive antigen test for Fusobacterium Nucleatum that utilizes the antigen-antibody reaction between magnetic nanoparticles and biological materials (antigens), which changes the magnetic flux passing through the small pickup coil. The magnetic flux of the pickup coil decreased with increasing antigen concentration because the density of magnetic nanoparticles decreased with increasing antigen concentration. The driving coil was air-cooled to reduce thermal drift, and the size of the differential pickup coil was reduced to achieve a high signal-to-noise ratio in magnetic flux measurements. After the antigen-antibody reaction, the magnetic nanoparticles and antigens are agglutinated by magnetic force, reducing the influence of contaminants and allowing the concentration of Fusobacterium Nucleatum to be evaluated without a washing step. The method was validated using samples collected from 28 individuals. The results showed a strong correlation with qPCR analysis (correlation coefficient = 0.69, p < 0.0001), highlighting the accuracy and precision comparable to conventional qPCR systems. The proposed approach offers several advantages for bacterial detection: low cost, rapid evaluation, high sensitivity, and minimal interference from contaminants.
- Open Access
- 9 December 2025
- Published by Springer Nature in Research Square
Noninvasive Breathomics for Developing Carbonyl Biomarkers in Esophageal Cancer
Background Despite being the gold standard for esophageal cancer (EC) diagnosis, the invasiveness and cost limit the use of upper gastrointestinal endoscopy for primary screening. We evaluated the potential of aldehyde profiling in exhaled breath condensate (EBC), a noninvasively obtained biofluid, as an EC diagnostic biomarker. Methods EBC, plasma, or saliva samples were collected from 152 patients with EC and 63 healthy controls (HC); aldehyde concentrations in EBC and plasma were measured using liquid chromatography–tandem mass spectrometry. Saliva microbiota was analyzed by 16S rRNA sequencing, focusing on oral acetaldehyde-producing bacteria. Results Among eight different aldehydes measured using EBC samples, acetaldehyde and formaldehyde concentrations were significantly higher in patients with EC than in HC, with elevations observed in both early and advanced-stage disease. Plasma acetaldehyde and formaldehyde levels were also increased in patients with EC compared with that in HC. EBC acetaldehyde and formaldehyde were identified as diagnostic biomarkers (areas under the curve: 0.77/0.87, sensitivities: 78%/89%, specificities: 70%/79%). It remains unclear whether the salivary microbiota influence the acetaldehyde concentration in EBC. Conclusions Acetaldehyde and formaldehyde in EBC are potential diagnostic biomarkers for EC. EBC is a noninvasive sample useful for screening with potential utility for early detection of EC.
- 9 December 2025
- Published by Springer Nature in Research Square
Open AccessNoninvasive Breathomics for Developing Carbonyl Biomarkers in Esophageal Cancer
Background Despite being the gold standard for esophageal cancer (EC) diagnosis, the invasiveness and cost limit the use of upper gastrointestinal endoscopy for primary screening. We evaluated the potential of aldehyde profiling in exhaled breath condensate (EBC), a noninvasively obtained biofluid, as an EC diagnostic biomarker. Methods EBC, plasma, or saliva samples were collected from 152 patients with EC and 63 healthy controls (HC); aldehyde concentrations in EBC and plasma were measured using liquid chromatography–tandem mass spectrometry. Saliva microbiota was analyzed by 16S rRNA sequencing, focusing on oral acetaldehyde-producing bacteria. Results Among eight different aldehydes measured using EBC samples, acetaldehyde and formaldehyde concentrations were significantly higher in patients with EC than in HC, with elevations observed in both early and advanced-stage disease. Plasma acetaldehyde and formaldehyde levels were also increased in patients with EC compared with that in HC. EBC acetaldehyde and formaldehyde were identified as diagnostic biomarkers (areas under the curve: 0.77/0.87, sensitivities: 78%/89%, specificities: 70%/79%). It remains unclear whether the salivary microbiota influence the acetaldehyde concentration in EBC. Conclusions Acetaldehyde and formaldehyde in EBC are potential diagnostic biomarkers for EC. EBC is a noninvasive sample useful for screening with potential utility for early detection of EC.
- Open Access
- 10 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1130
Prospective Survey of Postoperative Pain in Japan: A Multicenter, Observational Study
Background/Objectives: Postoperative analgesia is important for reducing biologically invasive reactions to surgery. In Japan, postoperative analgesia, including indices of analgesia, has not been adequately addressed. This study aimed to determine the relationship between postoperative pain and postoperative course and the importance of analgesia for early recovery. Methods: Patients who underwent any of seven surgical procedures in gastrointestinal, thoracic, and cardiac surgery were enrolled. The primary endpoint was a median Prince Henry Pain Scale score from postoperative days 1 to 3. Secondary endpoints were the quality of recovery on postoperative day 7 (Quality of Recovery-15 [QoR-15]) and the length of postoperative hospital stay. Results: Median postoperative pain levels among surgeries were 3 on day 1, 2 on days 2 and 3, 1 on day 7, and 1 at discharge. In both univariate and multivariate analyses, the use of postoperative epidural analgesia and intravenous patient-controlled analgesia (IV-PCA) were significant predictors of early postoperative pain. Only early postoperative pain was a significant predictor of QoR-15 score. Regular use of acetaminophen, early postoperative pain, no appetite, and postoperative complications were significant in affecting the length of postoperative hospital stay. In the comparison of early postoperative pain according to whether epidural analgesia and IV-PCA were used, the group that used both methods had the least pain. Conclusions: In Japan, early postoperative pain persists after major surgical procedures and affects postoperative quality of recovery and length of hospital stay. The use of epidural analgesia, IV-PCA, or both appeared to be effective in overcoming early postoperative pain, thereby enhancing early postoperative recovery.
- 10 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1130
Open AccessProspective Survey of Postoperative Pain in Japan: A Multicenter, Observational Study
Background/Objectives: Postoperative analgesia is important for reducing biologically invasive reactions to surgery. In Japan, postoperative analgesia, including indices of analgesia, has not been adequately addressed. This study aimed to determine the relationship between postoperative pain and postoperative course and the importance of analgesia for early recovery. Methods: Patients who underwent any of seven surgical procedures in gastrointestinal, thoracic, and cardiac surgery were enrolled. The primary endpoint was a median Prince Henry Pain Scale score from postoperative days 1 to 3. Secondary endpoints were the quality of recovery on postoperative day 7 (Quality of Recovery-15 [QoR-15]) and the length of postoperative hospital stay. Results: Median postoperative pain levels among surgeries were 3 on day 1, 2 on days 2 and 3, 1 on day 7, and 1 at discharge. In both univariate and multivariate analyses, the use of postoperative epidural analgesia and intravenous patient-controlled analgesia (IV-PCA) were significant predictors of early postoperative pain. Only early postoperative pain was a significant predictor of QoR-15 score. Regular use of acetaminophen, early postoperative pain, no appetite, and postoperative complications were significant in affecting the length of postoperative hospital stay. In the comparison of early postoperative pain according to whether epidural analgesia and IV-PCA were used, the group that used both methods had the least pain. Conclusions: In Japan, early postoperative pain persists after major surgical procedures and affects postoperative quality of recovery and length of hospital stay. The use of epidural analgesia, IV-PCA, or both appeared to be effective in overcoming early postoperative pain, thereby enhancing early postoperative recovery.
- Open Access
- 6 January 2025
- Published by Wiley in Pathology International
- Vol. 75 (2) , 82-91
Histopathological study of the localization/distribution of Fusobacterium nucleatum in esophageal cancer
Fusobacterium nucleatum is implicated in esophageal cancer; however, its distribution in esophageal cancer tissues remains unknown. This study aimed to clarify the presence and distribution of F. nucleatum in esophageal cancer tissues using fluorescence in situ hybridization (FISH). Tissues collected from 70 patients with esophageal squamous cell carcinoma were examined using FISH. Corresponding normal epithelium and metastatic lymph nodes were assessed. F. nucleatum was identified more frequently in esophageal cancer tissues than in the normal epithelium. F. nucleatum also showed significant correlation with factors associated with tumor progression, such as pT factor and tumor size. As tumor progression advanced, the area occupied by F. nucleatum gradually became larger. F. nucleatum positivity was observed around the deep edge of the tumor nest (border‐dense type) or identified diffusely in the tumor nest (diffuse distributed type). Furthermore, F. nucleatum was observed in metastatic lymph nodes, lesions of venous invasion, and walls of veins in normal epithelium. In conclusion, we visualized F. nucleatum using FISH and identified different distribution patterns of F. nucleatum, highlighting the spot density of its presence in tumor tissues. Recognizing this quantitative change is pivotal for establishing F. nucleatum as a reliable biomarker.
- 6 January 2025
- Published by Wiley in Pathology International
- Vol. 75 (2) , 82-91
Open AccessHistopathological study of the localization/distribution of Fusobacterium nucleatum in esophageal cancer
Fusobacterium nucleatum is implicated in esophageal cancer; however, its distribution in esophageal cancer tissues remains unknown. This study aimed to clarify the presence and distribution of F. nucleatum in esophageal cancer tissues using fluorescence in situ hybridization (FISH). Tissues collected from 70 patients with esophageal squamous cell carcinoma were examined using FISH. Corresponding normal epithelium and metastatic lymph nodes were assessed. F. nucleatum was identified more frequently in esophageal cancer tissues than in the normal epithelium. F. nucleatum also showed significant correlation with factors associated with tumor progression, such as pT factor and tumor size. As tumor progression advanced, the area occupied by F. nucleatum gradually became larger. F. nucleatum positivity was observed around the deep edge of the tumor nest (border‐dense type) or identified diffusely in the tumor nest (diffuse distributed type). Furthermore, F. nucleatum was observed in metastatic lymph nodes, lesions of venous invasion, and walls of veins in normal epithelium. In conclusion, we visualized F. nucleatum using FISH and identified different distribution patterns of F. nucleatum, highlighting the spot density of its presence in tumor tissues. Recognizing this quantitative change is pivotal for establishing F. nucleatum as a reliable biomarker.
- Open Access
- 13 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7611
Prevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy: Current Status and Future Perspectives
Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may experience permanent nerve dysfunction, severely impacting their quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. The management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy. This review article aims to inform esophageal surgeons and other clinicians about strategies for the prevention and management of recurrent laryngeal nerve palsy in esophagectomy.
- 13 December 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7611
Open AccessPrevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy: Current Status and Future Perspectives
Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may experience permanent nerve dysfunction, severely impacting their quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. The management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy. This review article aims to inform esophageal surgeons and other clinicians about strategies for the prevention and management of recurrent laryngeal nerve palsy in esophagectomy.
- Open Access
- 18 October 2024
- Published by MDPI AG in Preprints.org
Prevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy, Current Status and Future Perspectives
Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may result in permanent nerve dysfunction, severely impacting patient quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. Management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy.
- 18 October 2024
- Published by MDPI AG in Preprints.org
Open AccessPrevention and Management of Recurrent Laryngeal Nerve Palsy in Minimally Invasive Esophagectomy, Current Status and Future Perspectives
Recurrent laryngeal nerve palsy remains a significant complication following minimally invasive esophagectomy for esophageal cancer. Despite advancements in surgical techniques and lymphadenectomy precision, the incidence of recurrent laryngeal nerve palsy has not been improved. Recurrent laryngeal nerve palsy predominantly affects the left side and may lead to unilateral or bilateral vocal cord paralysis, resulting in hoarseness, dysphagia, and an increased risk of aspiration pneumonia. While most cases of recurrent laryngeal nerve palsy are temporary and resolve within 6 to 12 months, some patients may result in permanent nerve dysfunction, severely impacting patient quality of life. Prevention strategies, such as nerve integrity monitoring, robotic-assisted minimally invasive esophagectomy, and advanced dissection techniques, aim to minimize nerve injury, though their effectiveness varies. Management of recurrent laryngeal nerve palsy includes voice and swallowing rehabilitation, reinnervation techniques, and, in severe cases, surgical interventions such as thyroplasty and intracordal injection. As recurrent laryngeal nerve palsy can lead to significant postoperative respiratory complications, a multidisciplinary approach involving surgical precision, early detection, and comprehensive rehabilitation is crucial to improving patient outcomes and minimizing long-term morbidity in minimally invasive esophagectomy.
- Open Access
Perioperative Administration of Cystine and Theanine Suppresses Inflammation and Facilitates Early Rehabilitation and Recovery after Esophagectomy: A Randomized, Double-Blind, Controlled Clinical Trial
Oral administration of cystine and theanine (CT) increases glutathione levels to modulate the inflammatory response, which has yet to be sufficiently explored for patients’ recovery and early rehabilitation. We planned a randomized, double-blind, placebo-controlled trial to determine whether perioperative oral administration of CT promotes recovery after esophagectomy. Patients were randomized into either CT or placebo groups, who received preoperative and postoperative treatments for 4 and 13 days, respectively. The main outcome measures were triaxial accelerometer readings, inflammation indicators, a 6 min walk test (6MWT), and a quality of life questionnaire (QoR-40). The study involved 32 patients. Although the CT group (n = 16) showed better patient activity across the investigated period, there was no significant difference between the two groups. However, white blood cell count on postoperative days (POD) 2 and 10, neutrophil count (POD 2, 7, and 10), and C-reactive protein level (POD 13) in the CT group were significantly lower than in the placebo group. Furthermore, 6MWT on POD 7 and QoR-40 on POD 13 were significantly higher in the CT group than those in the placebo group. This study suggests that perioperative administration of CT may contribute to early recovery and rehabilitation after esophagectomy via suppression of inflammatory response.
Open AccessPerioperative Administration of Cystine and Theanine Suppresses Inflammation and Facilitates Early Rehabilitation and Recovery after Esophagectomy: A Randomized, Double-Blind, Controlled Clinical Trial
Oral administration of cystine and theanine (CT) increases glutathione levels to modulate the inflammatory response, which has yet to be sufficiently explored for patients’ recovery and early rehabilitation. We planned a randomized, double-blind, placebo-controlled trial to determine whether perioperative oral administration of CT promotes recovery after esophagectomy. Patients were randomized into either CT or placebo groups, who received preoperative and postoperative treatments for 4 and 13 days, respectively. The main outcome measures were triaxial accelerometer readings, inflammation indicators, a 6 min walk test (6MWT), and a quality of life questionnaire (QoR-40). The study involved 32 patients. Although the CT group (n = 16) showed better patient activity across the investigated period, there was no significant difference between the two groups. However, white blood cell count on postoperative days (POD) 2 and 10, neutrophil count (POD 2, 7, and 10), and C-reactive protein level (POD 13) in the CT group were significantly lower than in the placebo group. Furthermore, 6MWT on POD 7 and QoR-40 on POD 13 were significantly higher in the CT group than those in the placebo group. This study suggests that perioperative administration of CT may contribute to early recovery and rehabilitation after esophagectomy via suppression of inflammatory response.